In the time since its discovery, CRISPR has rapidly become an established tool in the genomics toolbox. Now the question is: What next?
The CRISPR 2.0 Summit is devoted to showcasing only the latest and greatest innovations by uncovering how the next generation of CRISPR tools are radically enhancing efficacy, minimizing off-target effects & enabling efficient delivery to specific tissues to ensure you stay at the forefront of this rapidly exploding field.
Discover the promise of novel Cas variants, base and prime editing approaches, innovative delivery mechanisms, and the applications of these next generation tools through learnings from CRISPR clinical trials and new & unpublished data.
Don’t get left behind. Join 100+ leading pharma and biotech companies pioneering CRISPR-based therapeutics into the clinic to usher in the next generation of safe, targeted and effective genome editing.
Rather than attending yet another CRISPR meeting that covers old ground, CRISPR 2.0 will offer you the opportunity to:
- Discuss methods to overcome CRISPR delivery challenges and delve into the latest delivery platforms with innovative work on the developments of viral and non-viral candidates suitable for ex-vivo and in-vivo delivery with Scribe Therapeutics and AskBio
- Explore the potential of novel prime and base editing, improving on editing accuracy. Hear directly from Andrew Anzalone, the pioneer that developed prime editing and Astrazeneca on how to improve safety
- Accelerate the development of therapeutics utilizing CRISPR and discover the clinical applications that are being studied with insights and data from Intellia Therapeutics, and Graphite Bio
- Investigate novel Cas variants and understand how novel Cas proteins that optimize specificity and efficacy of gene editing will be vital to bringing CRISPR successfully into the clinic with Arbor Biotech and Harvard Medical School
To know more about CRISPR 2.0 Summit please click here.